Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.42 |
| ▸ | CCR6 | P51684 | 3/20 | 0.39 |
| ▸ | CCR7 | P32248 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 3/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937510 | 1.00 | HCAR3 (0.42) | HCAR3CCR6CCR7BACE1KIT | |
| SCHEMBL1937694 | 0.84 | HCAR3 (0.54) | HCAR3CCR6SYK | |
| SCHEMBL1937691 | 0.84 | HCAR3 (0.54) | HCAR3CCR6SYK | |
| SCHEMBL15204516 | 0.80 | HCAR3 (0.48) | HCAR3CCR6SYK | |
| SCHEMBL15204517 | 0.80 | HCAR3 (0.48) | HCAR3CCR6SYK | |
| SCHEMBL15204853 | 0.80 | HCAR3 (0.48) | HCAR3CCR6SYK | |
| SCHEMBL3628624 | 0.77 | HCAR3 (0.50) | HCAR3CCR6CCR7BACE1SIRT6 | |
| SCHEMBL3628627 | 0.77 | HCAR3 (0.50) | HCAR3CCR6CCR7BACE1SIRT6 | |
| SCHEMBL1936258 | 0.77 | HCAR3 (0.49) | HCAR3CCR6CCR7KITFLT3 | |
| SCHEMBL1936260 | 0.77 | HCAR3 (0.49) | HCAR3CCR6CCR7KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2331507-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | HCAR3 195/4885CCR6 3938/4885CCR7 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.